Chemotherapy Effect Clinical Trial
Official title:
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary: A Prospective, Open-label, Single-arm Clinical Study
Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of patients with bone metastases cancer with unknown primary, and provide a better treatment plan for these patients. 1. Primary outcome: Objective response rate (ORR) 2. Secondary outcomes: disease control rate (DCR), duration of remission (DOR), progression-free disease (PFS), overall survival (OS), median PFS, median OS, stratification based on clinical features and PD-L1 expression, adverse reactions (AEs), and quality of life.
Status | Recruiting |
Enrollment | 27 |
Est. completion date | October 31, 2024 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Willing and able to provide written informed consent/consent for the trial. 2. Be at least 18 years old on the day of signing the informed consent. 3. Patients with bone metastases from cancer of unknown primary (BMCUP) diagnosed according to the criteria defined in the clinical practice guidelines of the European Society of Medical Oncology (ESMO) in 2015 and confirmed by imaging and histology to have bone metastases that cannot be completely resected. 4. Did not receive systemic treatment. 5. Have at least one measurable lesion according to RECIST1.1, willing to agree to archived tumor (in formalin fixed paraffin-embedded (FFPE) block) or fresh tumor material (cryogenic refrigerator or liquid nitrogen storage). 6. ECOG performance level 0 or 1 point. 7. The expected survival time is =3 months. 8. Adequate organ and bone marrow functions (all screening tests should be performed within 10 days of the start of treatment) :A) Absolute neutrophil count =1.5x109 /L.B) Platelet =100x109 /L.C) Hemoglobin =9g/dL(=90g/L).D) No blood transfusion or erythropoietin dependence (within 7 days of evaluation).E) Serum creatinine =1.5x upper normal limit (ULN) or creatinine level > 1.5xULn, creatinine clearance =60 ml/min (creatinine clearance should be calculated according to institutional criteria).F) Patients with serum total bilirubin =1.5xULN or total bilirubin level > 1.5ULN, direct bilirubin =ULN.G) Aspartate aminotransferase =2.5xULN(if liver metastasis is present).H) Alanine aminotransferase =2.5xULN(if liver metastasis is present).I) Albumin =2.5g/dL.J) International standardized ratio (INR) or prothrombin time =1.5xULN(if subject is being treated with anticoagulant, prothrombin time or partial prothrombin time should be within the range expected for treatment with anticoagulant).K) Activated partial thrombin time =1.5xULN(prothrombin time or partial prothrombin time should be within the expected therapeutic range of anticoagulant use).L) Women with reproductive potential should undergo a mandatory serum-negative pregnancy within 72 hours prior to receiving the first dose of the study drug.M) Fertile female subjects must be willing to use appropriate contraceptive methods during the study up to 120 days after the last use of the study drug.Note: Abstinence is acceptable if this is the subject's usual lifestyle and preferred method of contraception.N) Male subjects with reproductive potential must consent to use appropriate contraceptive methods from the first study treatment until 120 days after the last study treatment. Exclusion Criteria: 1. Unknown primary lesion of squamous cells. 2. in suspected lymphoma (e.g., leukocyte common antigen staining), malignant melanoma (for example, according to dye and beta hCG), gonads germ cell tumor (such as AFP and human chorionic gonadotropin), sarcoma (such as cell keratin and vimentin staining), neuroendocrine tumor (such as chromaffin granulocyte and synaptic staining).And male prostate cancer (e.g., prostate specific antigen staining). 3. apply to specific treatment, the patients of group (for example, only axillary lymph node metastasis of adenocarcinoma patients, peritoneal papillary serous carcinoma patients, only involving the neck, or groin lymph nodes of patients with squamous cell carcinoma, prompt germ cell tumors and beta hCG and/or AFP levels of patients with poorly differentiated carcinoma, and involves a single potentially resectable cancer patients). 4. Currently participating in and receiving study therapy, or participating in a study formulation and receiving study therapy or using study drug within 4 weeks of the first dose. 5. Confirmed immunodeficiency or receiving documented systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to receiving the first dose of tirelizumab. 6. Have active tuberculosis. 7. Have an allergic reaction to the study drug. 8. One has received radiotherapy within 14 days before the first treatment. If the subjects received radiotherapy, they must fully recover from the toxicity and / or complications caused by the intervention, according to the judgment of a qualified investigator, before starting the treatment. 9. Have received chemotherapy treatment. 10. Subjects must fully recover from surgery and related complications in the judgment of a qualified investigator prior to the initiation of treatment. 11. There is another known malignancy developing or requiring aggressive treatment.Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin, squamous cell carcinoma of the skin that has received potential treatment, or cervical carcinoma in situ. 12. Active central nervous system (CNS) metastases and/or cancerous meningitis are known.Brain metastasis treated subjects as long as they received in a stable condition (in the treatment of at least four weeks before the first trials there was no evidence of progress examined by CT or MRI brain, any neurological symptoms has returned to baseline), there was no evidence of brain metastases from new or expanded, and at least 7 days prior to treatment did not use steroids, can attend the test.This exception does not include cancerous meningitis, which is excluded regardless of clinical stability. 13. Active autoimmune disease requiring systematic treatment (i.e. disease improvers, corticosteroids, or immunosuppressants) within the past two years. 14. Having (noninfectious) pneumonia or a history of current pneumonia. 15. There is an active infection that requires systematic treatment. 16. History or current evidence of any condition, treatment or laboratory abnormality that is likely to confound the results of the study or interfere with the subject's participation throughout the study, or any history or evidence of any condition, treatment or laboratory abnormality that, in the opinion of a qualified investigator for the treatment, would not be in the subject's best interest to participate. 17. A known mental or substance abuse disorder interferes with compliance with test requirements. 18. The subject is pregnant or breast-feeding, or plans to become pregnant or a father during the expected duration of the trial, beginning with pre-screening or screening 120 calendar days after the last trial treatment and continuing 120 calendar days after the last trial treatment. 19. Once have received anti-PD-1, anti-PD-L1 or anti-PD-L2 preparation treatment. 20. A known history of human immunodeficiency virus (HIV). 21. Active hepatitis B (e.g., HBsAg reaction) or hepatitis C (e.g., detection of HCVRNA) is known. 22. Live vaccine should be administered within 30 calendar days of the planned initiation of study treatment. 23. Have a history of organ and/or bone marrow transplantation. |
Country | Name | City | State |
---|---|---|---|
China | ChangZheng Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Wei Xu |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Response(CR) and Partial Response(PR) in all participants according to RECIST,v1.1 | Proportion of patients whose tumor volume shrinks to a predetermined value and maintains the minimum time limit | 3 years | |
Secondary | Disease control rate(DCR)according to RECIST,v1.1 | Proportion of patients whose tumors shrank or remained stable for a certain amount of time | 3 years | |
Secondary | Duration of remission (DOR) by Kaplan-Meier | The time between the first tumor evaluation for CR or PR and the first evaluation for PD (Progressive Disease) or death from any cause | 3 years | |
Secondary | Progression Free Survival (PFS) by Kaplan-Meier | The time span from the start of treatment to the onset of secondary growth | 3 years | |
Secondary | Overall survival (OS) by Kaplan-Meier | The time between randomization and the death of the patient from any cause | 3 years | |
Secondary | The median of Progression Free Survival (PFS) by Kaplan-Meier | Fifty percent of patients survival with respect to the The time span from the start of treatment to the onset of secondary growth | 3 years | |
Secondary | The median of overall survival (OS) by Kaplan-Meier | Fifty percent of patients survival with respect to The time between randomization and the death of the patient from any cause | 3 years | |
Secondary | Stratified analysis based on clinical features and PD-L1 expression | Stratified analysis | 3 years | |
Secondary | Adverse effects (AEs) according to NCI-CTCAE, v5.0 | The occurrence of adverse events was recorded | 3 years | |
Secondary | The quality of life according to QoF(sf-36) | Quality of life was recorded | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06376604 -
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
|
N/A | |
Completed |
NCT03753542 -
Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy
|
N/A | |
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Completed |
NCT04207359 -
Effects of Creatine Supplementation in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT04173195 -
Comfort Talk (CT) During Outpatient Chemotherapy
|
N/A | |
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Recruiting |
NCT03275194 -
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
|
Phase 2 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Completed |
NCT05131490 -
Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients
|
N/A | |
Completed |
NCT04118322 -
The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy
|
N/A | |
Recruiting |
NCT06043999 -
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04989985 -
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Recruiting |
NCT05424692 -
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A |